As IgE plays a significant role in the pathology of FA, the investigation of an anti-IgE therapy for FA is well reasoned.50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63 TNX-901 (talizumab) was the first anti-IgE to be studied in the treatment of FA and was shown to protect most patients against allergic reactions from accidental peanut exposure by substantially increasing the peanut reaction threshold.50 This evidence concerns the gene IGHE and allergic disease.